Utility of thromboelastography platelet mapping in bleeding disorders – An experience from Eastern India
Background and Objectives: Thromboelastography platelet mapping (TEG-PM) is primarily used to monitor the effectiveness of antiplatelet medications by assessing the inhibition of thromboxane A2 and adenosine diphosphate (ADP) receptors. The objective of this study was to understand the utility of TE...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2020-01-01
|
| Series: | Global Journal of Transfusion Medicine |
| Subjects: | |
| Online Access: | http://www.gjtmonline.com/article.asp?issn=2468-8398;year=2020;volume=5;issue=2;spage=202;epage=205;aulast=Datta |
| _version_ | 1830382257702961152 |
|---|---|
| author | Suvro Sankha Datta De Dibyendu |
| author_facet | Suvro Sankha Datta De Dibyendu |
| author_sort | Suvro Sankha Datta |
| collection | DOAJ |
| description | Background and Objectives: Thromboelastography platelet mapping (TEG-PM) is primarily used to monitor the effectiveness of antiplatelet medications by assessing the inhibition of thromboxane A2 and adenosine diphosphate (ADP) receptors. The objective of this study was to understand the utility of TEG-PM assay in suspected cases of bleeding disorders. Materials and Methods: A total of 20 suspected cases of bleeding disorders were tested by TEG-PM assay as a primary screening test. The percentage of platelet aggregation to agonist was calculated by: ([MAADP/AA– MAFibrin]/[MAThrombin– MAFibrin] × 100) and inhibition by: (100% – % aggregation). The cutoff was defined as >50% inhibition for each agonist. Light transmittance aggregometry (LTA) was performed when the inhibition was >50% both with ADP and arachidonic acid (AA). Results: Ten out of 20 patients were showing an inhibition >50% with ADP and 5 among 20 had an inhibition >50% with AA. Among four patients who had >50% inhibition with both agonists, two cases were diagnosed as Glanzmann's thrombasthenia by LTA and one case was diagnosed as Wiskott–Aldrich syndrome by genetic analysis. Final diagnosis was not made in one case as LTA was inconclusive. Conclusion: We believe that TEG-PM assay may be introduced in preliminary algorithm for the diagnosis of bleeding disorders where facility such as LTA is not easily available. |
| first_indexed | 2024-12-20T10:03:19Z |
| format | Article |
| id | doaj.art-c6bbf3bfe5bb4d718ffdd498304e482c |
| institution | Directory Open Access Journal |
| issn | 2468-8398 2455-8893 |
| language | English |
| last_indexed | 2024-12-20T10:03:19Z |
| publishDate | 2020-01-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Global Journal of Transfusion Medicine |
| spelling | doaj.art-c6bbf3bfe5bb4d718ffdd498304e482c2022-12-21T19:44:17ZengWolters Kluwer Medknow PublicationsGlobal Journal of Transfusion Medicine2468-83982455-88932020-01-015220220510.4103/GJTM.GJTM_75_20Utility of thromboelastography platelet mapping in bleeding disorders – An experience from Eastern IndiaSuvro Sankha DattaDe DibyenduBackground and Objectives: Thromboelastography platelet mapping (TEG-PM) is primarily used to monitor the effectiveness of antiplatelet medications by assessing the inhibition of thromboxane A2 and adenosine diphosphate (ADP) receptors. The objective of this study was to understand the utility of TEG-PM assay in suspected cases of bleeding disorders. Materials and Methods: A total of 20 suspected cases of bleeding disorders were tested by TEG-PM assay as a primary screening test. The percentage of platelet aggregation to agonist was calculated by: ([MAADP/AA– MAFibrin]/[MAThrombin– MAFibrin] × 100) and inhibition by: (100% – % aggregation). The cutoff was defined as >50% inhibition for each agonist. Light transmittance aggregometry (LTA) was performed when the inhibition was >50% both with ADP and arachidonic acid (AA). Results: Ten out of 20 patients were showing an inhibition >50% with ADP and 5 among 20 had an inhibition >50% with AA. Among four patients who had >50% inhibition with both agonists, two cases were diagnosed as Glanzmann's thrombasthenia by LTA and one case was diagnosed as Wiskott–Aldrich syndrome by genetic analysis. Final diagnosis was not made in one case as LTA was inconclusive. Conclusion: We believe that TEG-PM assay may be introduced in preliminary algorithm for the diagnosis of bleeding disorders where facility such as LTA is not easily available.http://www.gjtmonline.com/article.asp?issn=2468-8398;year=2020;volume=5;issue=2;spage=202;epage=205;aulast=Dattableeding disordersplatelet-mappingthromboelastography |
| spellingShingle | Suvro Sankha Datta De Dibyendu Utility of thromboelastography platelet mapping in bleeding disorders – An experience from Eastern India Global Journal of Transfusion Medicine bleeding disorders platelet-mapping thromboelastography |
| title | Utility of thromboelastography platelet mapping in bleeding disorders – An experience from Eastern India |
| title_full | Utility of thromboelastography platelet mapping in bleeding disorders – An experience from Eastern India |
| title_fullStr | Utility of thromboelastography platelet mapping in bleeding disorders – An experience from Eastern India |
| title_full_unstemmed | Utility of thromboelastography platelet mapping in bleeding disorders – An experience from Eastern India |
| title_short | Utility of thromboelastography platelet mapping in bleeding disorders – An experience from Eastern India |
| title_sort | utility of thromboelastography platelet mapping in bleeding disorders an experience from eastern india |
| topic | bleeding disorders platelet-mapping thromboelastography |
| url | http://www.gjtmonline.com/article.asp?issn=2468-8398;year=2020;volume=5;issue=2;spage=202;epage=205;aulast=Datta |
| work_keys_str_mv | AT suvrosankhadatta utilityofthromboelastographyplateletmappinginbleedingdisordersanexperiencefromeasternindia AT dedibyendu utilityofthromboelastographyplateletmappinginbleedingdisordersanexperiencefromeasternindia |